A 33-year-old woman hears brutal and frightening voices daily but continues her college studies. A middle-aged man, who served in the Navy and has since struggled with substance abuse, spends 10 weeks ...

Positive symptoms of schizophrenia include delusions, hallucinations, and other changes in thoughts or behaviors. Schizophrenia is a mental health disorder that affects your thoughts, behaviors, and ...

Panelists discuss how understanding and managing the full range of schizophrenia symptoms is key to improving long-term patient outcomes. Panelists discuss how schizophrenia presents a wide spectrum ...

Cognitive issues are core symptoms of schizophrenia. More than 80 percent of people with schizophrenia have cognitive symptoms of some kind. They’re one of the main obstacles to managing schizophrenia ...

“Exercise is not a replacement for psychiatric medication for the treatment of schizophrenia. However, exercise is a low-risk, worthwhile adjunctive [add-on] intervention,” says Divya Hedgren, MD, a ...

Repetitive transcranial magnetic stimulation (rTMS) is both safe and effective for treating nonexistent spoken voices heard by patients with schizophrenia, new research showed. In a randomized, sham ...

Relapses are often associated with a major disruption in a person’s life, such as a job loss or legal problem. They’re usually preceded by early warning signs that appear a week or so in advance, says ...

A man with schizophrenia has shared footage of the moment a service dog came to his aid after he began experiencing "visual hallucinations." Schizophrenia—a mental health condition that manifests ...

Credit: Bristol Myers Squibb. Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors. Data from the EMERGENT ...

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of schizophrenia in adults. The FDA approved xanomeline and trospium chloride (Cobenfy) ...

In November, the Boston-based biotech firm Karuna Therapeutics submitted its new schizophrenia medication, called KarXT, to the US Food and Drug Administration for approval. If the agency gives KarXT ...